ENTITY

Genfleet Therapeutics (2595 HK)

38
Analysis
Health Care • China
Genfleet Therapeutics is a biopharmaceutical company focused on developing innovative treatments for oncology, including various solid tumors, and autoimmune and inflammatory diseases. The company's pipeline includes products like GFH925 (fulzerasib) for advanced non-small cell lung cancer and GFH375, a KRAS G12C inhibitor. Genfleet Therapeutics was incorporated in 2017 and is headquartered in Shanghai, China.
more
bullish•Quantitative Analysis
•19 Jul 2026 10:05

HK Connect Flows Weekly (Jul 17th): Knowledge Atlas, Alibaba, Ntes, Iluvatar Corex, Gigadevice

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Knowledge Atlas (2513 HK), Alibaba (9988 HK), Ntes (9999...

Logo
131 Views
Share
bullish•Quantitative Analysis
•12 Jul 2026 10:05

HK Connect Flows Weekly (Jul 10th): Tencent, Knowledge Atlas, Alibaba, Kingboard Laminates, Smic

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Tencent (700 HK), Knowledge Atlas (2513 HK), Alibaba...

Logo
117 Views
Share
bearish•Tyligand Bioscience
•10 Jul 2026 08:55

Pre-IPO Tyligand Bioscience - Concerns on KRAS Will Directly Limit the Valuation Ceiling

​Investors wary of early KRAS G12D projects, demand higher risk premiums. Validation needed for TSN1611 and TSN222. Tyligand's valuation may not...

Logo
143 Views
Share
bearish•Quantitative Analysis
•05 Jul 2026 10:05

HK Connect Flows Weekly (Jul 3rd): Kingboard Laminates, Smic, Alibaba, Kingboard, China Mobile

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Kingboard Laminates (1888 HK), Smic (981 HK), Alibaba...

Logo
117 Views
Share
•28 May 2026 10:00

HK IPO Essential Statistics: Quantifying Lock-Up Expiry Overhang

HK IPO Essential Stat: We studied 43 HK IPO cornerstone deals listed in 2025 to quantify the selling pressure upon lock-up expiry.

Logo
203 Views
Share
x